Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novavax Sets Out Vaccine Strategy For New COVID-19 Variants

Share Price Wobbles On Filing Uncertainty

Executive Summary

The US company is poised to file with regulators in Q2, but is also looking for longer-term competitive advantage in its variant strategy.

You may also be interested in...



COVID-19 Vaccine Regulatory Strategy Evolving With The Pandemic

AstraZeneca and Novavax have not filed EUAs for their vaccines, and they never might. The pathway remains viable in the short-term, but as BLAs are approved and supplies are no longer short, the window may close.

Pandemic Perspectives: One Year On, COVID-19 Vaccines Are Turning The Tide

12 months on since SARS-CoV2 was declared a pandemic, there are now 10 vaccines authorized internationally. But producing and administering doses for the whole world - and keeping ahead of 'variants of concern' - is a huge global challenge.

UK’s Real-World Data Shows Value Of Initial COVID Vaccines Doses – But Can It Shift Policy Elsewhere?

Another real-world study from the UK’s rapid vaccine rollout provides evidence that Pfizer’s vaccine saves lives, with the AstraZeneca shot matching it on cutting hospitalizations.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC143918

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel